LEUKOTAC ® (inolimomab) is available again in France, following the granting of cohort ATU for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV LEUKOTAC ® (inolimomab) is available again in France, following the granting of cohort ATU for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with...

L’analyse de survie à long terme de l’étude de phase III randomisée démontre un bénéfice clinique évident de l’inolimomab dans le traitement de la SR-aGvHD L’analyse de survie à long terme de l’étude de phase III randomisée démontre un bénéfice clinique évident de l’inolimomab dans le traitement de la SR-aGvHD Le suivi des patients de l’étude de phase...

Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD Follow-up of INO-107 Phase III study patients up to 8.5 years is the first...